|
Market Closed -
Other stock markets
|
After hours 08:00:00 pm | |||
| 27.47 USD | -0.94% |
|
27.34 | -0.46% |
| Feb. 12 | Verrica Pharmaceuticals Inc. Appoints Chris Chapman as Chief Commercial Officer | CI |
| Feb. 12 | Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap… |  |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
EBT: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Global Biopharmaceuticals Business (Biopharma) | 41.91B | 79.56B | 98.99B | 57.19B | 62.4B | |||||
Interest Expense | -1.45B | - | - | - | - | |||||
Income Tax Expense | 477M | - | - | - | - | |||||
Total Assets | 154B | - | - | - | - | |||||
CAPEX | -2.79B | - | - | - | - | |||||
EBT | 7.5B | 40.23B | 57.15B | 30.63B | 28.14B | |||||
D&A | 4.76B | 1.44B | 813M | 882M | 1.36B | |||||
Net Income | 9.62B | - | - | - | - | |||||
Upjohn | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Innovative Health (IH) | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Essential Health (EH) | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Global Vaccines, Oncology and Consumer Healthcare (VOC) | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Global Innovative Pharmaceutical (GIP) | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Life Sciences Tools and Services | ||||||||||
Pfizer Centreone (PC1) | - | - | - | - | 1.15B | |||||
Pfizer Ignite | - | - | - | - | 82M | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
EBT | - | -2.29B | -3.61B | -3.92B | -5.51B | |||||
D&A | - | 87M | 36M | - | - | |||||
EBT | - | -52M | -832M | -1.87B | -1.94B | |||||
D&A | - | - | -20M | -11M | 12M | |||||
EBT | - | -3.18B | - | - | - | |||||
D&A | - | 3.07B | - | - | - | |||||
EBT | - | - | -3.61B | -4.73B | -5.29B | |||||
D&A | - | - | 3.61B | 4.73B | 5.29B | |||||
Pharmaceutical Contract Manufacturing Services | ||||||||||
Other business activities | - | 1.73B | 1.34B | 1.31B | - | |||||
EBT | - | -10.4B | -14.37B | -19.05B | -7.38B | |||||
D&A | - | 598M | 626M | 654M | 340M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 21.71B | 29.75B | 42.47B | 27.09B | 38.69B | |||||
Total Assets | 7.82B | 8.38B | 9.18B | 10.67B | 9.75B | |||||
Developed Markets | - | - | - | - | 16.06B | |||||
Total Assets | - | - | - | - | 7.19B | |||||
Emerging Markets | 8.37B | 20.7B | 20.1B | 12B | 8.88B | |||||
Total Assets | 890M | 1.06B | 1.41B | 1.76B | 1.46B | |||||
Developed Europe | 7.79B | 18.34B | 21.98B | 11.65B | - | |||||
Total Assets | 4.78B | 5.09B | 5.39B | 6.22B | - | |||||
International | 4.04B | 12.51B | 15.78B | 7.76B | - | |||||
Total Assets | 413M | 347M | 293M | 290M | - |
- Stock Market
- Equities
- PFE Stock
- Financials Pfizer Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
